CLDX FY 2013 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

FY 2013 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-63.3% YoY

Gross Profit

$2M43.2% margin

Operating Income

-$81M-1981.1% margin

Net Income

-$82M-1983.7% margin

EPS (Diluted)

$-15.33

Cash Flow

Operating Cash Flow

-$68M

Free Cash Flow

-$72M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$347M

Total Liabilities

$27M

Stockholders' Equity

$320M

Cash & Equivalents

$169M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$11M	-63.3%
Gross Profit	$2M	$427,000	+316.2%
Operating Income	-$81M	-$58M	-40.2%
Net Income	-$82M	-$59M	-37.9%